ICER updates report on targeted treatments for plaque psoriasis

The USA’s Institute for Clinical and Economic Review (ICER) on Friday released a Final Condition Update report and Report-at-a-Glance on targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis..

This update incorporates new clinical data and cost information for previously reviewed therapies, and includes analyses of more recently approved medications Tremfya (guselkumab) from Johnson & Johnson (NYSE: J NJ), Ilumya (tildrakizumab) from Sun Pharma (BSE: 524715) and Merck & Co (NYSE: MRK), and Cimzia (certolizumab pegol) from UCB (Euronext Brussels: UCB), as well as risankizumab from AbbVie (NYSE: ABBV)), which is currently being reviewed by the Food and Drug Administration.

ICER’s condition update report was reviewed at a July 2018 public meeting of the New England Comparative Effectiveness Public Advisory Council ( New England CEPAC), one of ICER’s three independent evidence appraisal committees. During the meeting, the New England CEPAC voted that, compared to TNFα inhibitors, both guselkumab and risankizumab offer a superior net health benefit based on currently-available evidence. The Council further voted that evidence was not adequate to show a net health benefit of tildrakizumab compared to TNFα inhibitors, or of the TNFα inhibitor certolizumab pegol over the other subcutaneously-administered TNFα inhibitors (adalimumab and etanercept).